1. Home
  2. FDSB vs SBFM Comparison

FDSB vs SBFM Comparison

Compare FDSB & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FDSB
  • SBFM
  • Stock Information
  • Founded
  • FDSB 1926
  • SBFM 2006
  • Country
  • FDSB United States
  • SBFM United States
  • Employees
  • FDSB N/A
  • SBFM N/A
  • Industry
  • FDSB
  • SBFM Biotechnology: Pharmaceutical Preparations
  • Sector
  • FDSB
  • SBFM Health Care
  • Exchange
  • FDSB NYSE
  • SBFM Nasdaq
  • Market Cap
  • FDSB N/A
  • SBFM 4.9M
  • IPO Year
  • FDSB N/A
  • SBFM N/A
  • Fundamental
  • Price
  • FDSB $11.97
  • SBFM $1.51
  • Analyst Decision
  • FDSB
  • SBFM Strong Buy
  • Analyst Count
  • FDSB 0
  • SBFM 1
  • Target Price
  • FDSB N/A
  • SBFM $15.00
  • AVG Volume (30 Days)
  • FDSB 3.8K
  • SBFM 4.3M
  • Earning Date
  • FDSB 05-15-2025
  • SBFM 05-19-2025
  • Dividend Yield
  • FDSB N/A
  • SBFM N/A
  • EPS Growth
  • FDSB N/A
  • SBFM N/A
  • EPS
  • FDSB N/A
  • SBFM N/A
  • Revenue
  • FDSB $10,664,000.00
  • SBFM $34,874,283.00
  • Revenue This Year
  • FDSB N/A
  • SBFM $192.48
  • Revenue Next Year
  • FDSB N/A
  • SBFM N/A
  • P/E Ratio
  • FDSB N/A
  • SBFM N/A
  • Revenue Growth
  • FDSB N/A
  • SBFM 44.75
  • 52 Week Low
  • FDSB $9.85
  • SBFM $1.17
  • 52 Week High
  • FDSB $14.50
  • SBFM $33.60
  • Technical
  • Relative Strength Index (RSI)
  • FDSB N/A
  • SBFM 43.22
  • Support Level
  • FDSB N/A
  • SBFM $1.17
  • Resistance Level
  • FDSB N/A
  • SBFM $1.59
  • Average True Range (ATR)
  • FDSB 0.00
  • SBFM 0.17
  • MACD
  • FDSB 0.00
  • SBFM 0.04
  • Stochastic Oscillator
  • FDSB 0.00
  • SBFM 70.89

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

Share on Social Networks: